KMPH News and Press, KemPharm Inc From 04/21/21

Eligible to Receive Additional Near-Term $10 Million Milestone Payment Following DEA Scheduling of SDX CELEBRATION, Fla., April 21, 2021 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prod...

On Thursday, 4/9/2021, KemPharm announced an updated commercialization agreement with its marketing partner, Corium. This was based on a post-approval commercial assessment conducted with GPC, Corium's parent. The agreement added increased royalty rates, and $130M in potential sales m...

KemPharm (KMPH) announces an amendment to the definitive collaboration and license agreement with an affiliate of private investment firm Gurnet Point Capital.Under the terms of the amended License Agreement, KemPharm is now eligible to receive a more than $100M bump in future regulatory and ...

Amendment Increases Total Potential Regulatory and Sales Milestone Payments to $590 Million, and Adds a New Top-Level Tier for Royalties on U.S. Net Sales Conference Call and Live Audio Webcast Scheduled for Today, Thursday, April 8, at 4:30 p.m. ET CELEBRATION, Fla., Apri...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips KemPharm, Inc. (NASDAQ: KMPH ) has had a really dazzling run-up in the past year. KMPH stock is up 191% over the trailing-12-month period (TTM) as a sort of short-squeeze took effect at the end of last year. Unfortuna...

Can-Fite BioPharma Ltd. (CANF) +87% on out-licensing psoriasis, liver disease drug rights.SunLink Health Systems, Inc. (SSY) +55% on announcing $2 Million expansion, capital and operating improvements at Trace Regional Hospital.Annovis Bio, Inc. (ANVS) +37% as ANVS401 improves ...

This continues our series on busting options myths where we explore a different way to sell options. In this article, we discuss myths around selling puts. These myths generally teach: (i) only sell puts on companies you wouldn't mind owning; (ii) selling puts requires a neutral t...

KemPharm, Inc. (KMPH) Q4 2020 Earnings Conference Call March 11, 2021 04:30 PM ET Company Participants Jason Rando - Tiberend Strategic Advisors, Inc. Travis Mickle - President, CEO LaDuane Clifton - CFO Conference Call Participants Presentation Operator Ladies and gentlemen, thank you for st...

KemPharm (KMPH): Q4 Non-GAAP EPS of -$1.07 misses by $0.40.Revenue of $2.4M beats by $0.44M.As of December 31, 2020, total cash, cash equivalents and restricted cash was $4.3M.Shares -1.8% AH.Press Release For further details see: KemPharm EPS misses by $0.40, beats on revenue

Corporate and Regulatory Highlights: AZSTARYS™ NDA approved by the FDA on March 2, 2021 Co-hosted “KP415 Market Opportunity and Commercialization Strategy” Investor Event with Corium, Inc. Received FDA clearance to initiate KP879 clinical progra...